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Abstract 
Background: Dependence on cocaine causes significant functional impairment and morbidity in users and 
is extremely prevalent in the U.S. Unlike other abused substances, there is currently no effective standard 
of treatment to decrease cocaine cravings and prevent relapse. This systematic review assesses whether 
recent research shows that repetitive transcranial magnetic stimulation (rTMS) is an effective treatment 
to decrease cocaine use. 
Methods: An exhaustive search of the medical literature databases was performed using Medline-Ovid, 
CINAHL, and Web of Science with the search words “cocaine” and “transcranial magnetic stimulation”. 
The studies reviewed were chosen based on inclusion and exclusion criteria and were assessed for 
quality using the GRADE criteria. 
Results: There have only been two studies performed on rTMS’s effects on cocaine use specifically, which 
were both included in this review. Both studies showed evidence that rTMS decreases cocaine use. One 
study showed a significant increase in abstinence during, and up to 6 months after rTMS treatment and a 
significant decrease in cravings as a secondary outcome. The second study did not show a significant 
decrease in cocaine use for the rTMS group until an exploratory analysis was done. The quality of both 
studies was low to moderate based on the GRADE criteria. 
Conclusion: Despite the small number of studies assessing rTMS’s effectiveness on decreasing cocaine 
use and their low to moderate quality of evidence based on the GRADE criteria, the 2 studies reviewed 
here show promising evidence that rTMS can successfully decrease cocaine use. Trials with a larger 
sample size and higher attrition rate are required to more clearly show whether rTMS has a positive effect 
on decreasing cocaine use. Despite these limitations, since effective treatments are not currently 
available, the risk of rTMS treatment is low, and the cost of continued cocaine dependence is extremely 
high, rTMS treatment should be considered for patients trying to abstain from cocaine use. 
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Abstract 
Background: Dependence on cocaine causes significant functional impairment and morbidity in 
users and is extremely prevalent in the U.S. Unlike other abused substances, there is currently no 
effective standard of treatment to decrease cocaine cravings and prevent relapse. This systematic 
review assesses whether recent research shows that repetitive transcranial magnetic stimulation 
(rTMS) is an effective treatment to decrease cocaine use. 
Methods:  An exhaustive search of the medical literature databases was performed using 
Medline-Ovid, CINAHL, and Web of Science with the search words “cocaine” and “transcranial 
magnetic stimulation”. The studies reviewed were chosen based on inclusion and exclusion 
criteria and were assessed for quality using the GRADE criteria.  
Results:  There have only been two studies performed on rTMS’s effects on cocaine use 
specifically, which were both included in this review. Both studies showed evidence that rTMS 
decreases cocaine use. One study showed a significant increase in abstinence during, and up to 6 
months after rTMS treatment and a significant decrease in cravings as a secondary outcome. The 
second study did not show a significant decrease in cocaine use for the rTMS group until an 
exploratory analysis was done. The quality of both studies was low to moderate based on the 
GRADE criteria.  
Conclusion:  Despite the small number of studies assessing rTMS’s effectiveness on decreasing 
cocaine use and their low to moderate quality of evidence based on the GRADE criteria, the 2 
studies reviewed here show promising evidence that rTMS can successfully decrease cocaine 
use. Trials with a larger sample size and higher attrition rate are required to more clearly show 
whether rTMS has a positive effect on decreasing cocaine use. Despite these limitations, since 
effective treatments are not currently available, the risk of rTMS treatment is low, and the cost of 
continued cocaine dependence is extremely high, rTMS treatment should be considered for 
patients trying to abstain from cocaine use.  
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Decreasing Cocaine Use with Repetitive Transcranial Magnetic Stimulation 
 
BACKGROUND 
 
Cocaine causes morbidity of multiple organ systems, increased risk taking, violent 
behavior, and fetal drug exposure. There were an estimated 18.2 million cocaine users worldwide 
in 2016,1 which is about 0.3-0.4% of the population 15-65 years old.2 Individuals with cocaine 
use disorder (CUD) tend to chronically relapse after attempts to abstain, in part because there are 
currently no proven effective pharmacological, psychotherapy, or somatic treatments to help 
individuals quit using.2,3 
A study3 has shown that cocaine users have decreased brain volume and neurotransmitter 
dysfunction. Cocaine use increases dopamine release in the reward system part of the brain, the 
Ventral Tegmental Area – Nucleus Accumbens Pathway (VTA-NAc), which contributes to the 
addictive nature of the drug. After individuals with CUD are detoxed, there is a decrease in 
dopamine D2 receptors (DA D2) and dopamine (DA) release in the VTA-NAc pathway4,5 which 
contributes to relapse as the detoxed individuals crave dopamine. Additionally, there is a 
decrease in dorsolateral prefrontal cortex (DLPFC) activity in individuals with CUD. The 
DLPFC transmits dopamine to the anterior cingulate cortex (ACC), which is involved in 
inhibitory control over rewarding stimulus. Decreased dopamine transmission from the DLPFC 
to the ACC can cause loss of control over cocaine cravings.3,4 Thus, increasing dopamine may 
decrease the chance of relapse.4 
Repetitive transcranial magnetic stimulation (rTMS) has been used since 1985 to treat 
individuals with depression and has been proven to be extremely effective and relatively safe. In 
2008, the U.S. FDA approved rTMS as a treatment for depression and many insurances now 
cover the procedure.  
An enormous amount of research has also been done in the last seven years to show the 
effectiveness of rTMS on decreasing alcohol and nicotine cravings. The dopaminergic pathway 
that is responsible for cravings in cocaine are the same pathways involved in alcohol and 
nicotine dependence and to some extent responsible for depression.11  
Repetitive transcranial magnetic stimulation (rTMS) provides a relatively safe, non-
invasive, non-pharmacological treatment by electromagnetically stimulating neural pathways in 
the brain3, and changing dysfunctional neural circuits.2 The extent and depth of rTMS depends on 
the shape and size of the coil used to deliver magnetic stimulation to the brain.3 Traditional rTMS 
uses a figure-of-eight coil which stimulates the cortex about 2-2.5cm deep.4 The H-coil 
stimulates the subcortex up to 6 cm deep2 and is shown to have more consistent results than the 
figure-of-eight coil.4 The 5 studies2-6 that have been completed on the use of rTMS to treat CUD 
and  reduce cocaine craving, use either the figure-of-eight or the H-coil. Theta Burst Stimulation 
(iTBS) is a new form of rTMS. Two studies7,8 currently in progress have been submitted to NIH 
that assess the effectiveness of iTBS on cocaine use and cravings. 
Of the 5 studies that have been completed on the use of rTMS to treat CUD, 4 of the 
studies2,3,5,6 used ratings of cravings as an outcome, and 2 of the studies3,4 used cocaine use as an 
outcome. This review evaluates the 2 studies that used cocaine use as an outcome, since this 
outcome appears to be a more reliable objective measure of the effectiveness of rTMS than 
subjective ratings of cocaine cravings.  
METHODS 
 
An exhaustive search of medical literature databases was performed using MEDLINE-
Ovid, CINAHL-EBSCO, and Web of Science with the search words “cocaine” and “transcranial 
magnetic stimulation”. Eligible studies for this review were published in the English language 
and used human subjects only.  A search of the National Institute of Health database for ongoing 
trials was performed to be used in the discussion of future research. The 5 studies that were 
found that used rTMS to treat cocaine use were reviewed. The selected studies were assessed for 
quality using the Grading of Recommendations Assessment, Development and Evaluation 
(GRADE) Working Group guidelines.16  
RESULTS 
 
 Fifty-six articles were found during the initial search of Web of Science, 3 from 
MEDLINE-Ovid and 4 from CINAHL. All 3 of the results from MEDLINE and 3 of the results 
from CINAHL were duplicates of the results from Web of Science.  All of the titles of the 
articles were screened to find studies that met the inclusion criteria. The abstracts of 20 studies 
that appeared to meet inclusion criteria from the nature of the titles were read. Five studies that 
used rTMS to treat cocaine dependence were read in full. These studies used either cocaine 
cravings or cocaine use as an outcome. Trials using cocaine use as an outcome were chosen as 
the subject of this review due to being a more objective measure of decreasing cocaine use than 
cocaine cravings and decreasing cocaine use as being the ultimate goal of cocaine 
treatment.  There were 2 RCTs3,4 that met all inclusion criteria for this review of literature. See 
Table 1. Six articles were found that reviewed rTMS’s effects on substance abuse in general and 
one specifically on rTMS’s effects on cocaine. These articles were read for background 
information on the subject. The National Institute for Health’s website was searched to find any 
ongoing trials. There is currently one trial9  in process that meets criteria for this review that is not 
recruiting yet. 
 
 
 
 
Bolloni et al 
 
 The Bolloni et al study,4 conducted at the National Health Institute of Addiction of 
Marsciano, Italy in November of 2014, was a double blinded randomized controlled trial (RCT) 
in which subjects were either assigned to a rTMS treatment group or a sham group that received 
a placebo treatment of rTMS. The experimental procedure of the trial compared the 2 groups for 
cocaine use by analyzing the subject’s hair samples at time T0 (before treatment), T1 (end of 
treatment 4 weeks later), T2 (3 months post treatment), and T3 (6 months post treatment). The 
hair samples were tested for quantities of cocaine, cannabis, and opioids using a set of guidelines 
provided by the Society of Hair Testing. Originally there were a total of 18 subjects identified 
with CUD seeking outpatient treatment. Inclusion criteria were patients aged 18 and 65 years, 
with a minimum cocaine use of .05-20 ng/mg at least 2 days per week for the 4 weeks leading up 
to the trial, and with the ability to comprehend and sign the informed consent form. Exclusion 
criteria were patients with other substance use disorders, ongoing mental health issues, serious 
medical illness, requiring the use of medical devices, history of epilepsy, pregnancy, or current 
enrollment in other clinical trials. Of the 18 patients identified, 4 subjects were dismissed from 
the trial for cocaine use levels higher than the accepted range. Four other subjects did not finish 
the treatment phase and were labeled as dropouts. By the end of the study, 10 subjects (8 males, 
2 females) were included in the statistical analysis.4 See Table 2. 
The treatment group received 10 hz stimulations from a H1-coil rTMS device aimed to 
stimulate the prefrontal cortex bilaterally.4 There were 12 stimulations, 3 per week, spaced 
equally over the 4-week treatment period. Each stimulation consisted of 20 runs of 50 pulses 
with 15 second breaks between, totaling 1000 pulses in a 10-minute session. The same treatment 
setting and schedule was used with the sham group using an rTMS device that made an identical 
sound as functioning machines without emitting magnetic stimulation. Initially there was no 
major outcome difference regarding cocaine use between the 2 groups; however, an exploratory 
analysis using a one-way analysis of variance was conducted to assess the use of cocaine over 
time. The exploratory analysis showed a significant decrease in cocaine use from time T0-T2 and 
T0-T3 in the treatment group, but not the sham group.4  
Limitations of this study were its small sample size and participant attrition. The initial 
subject pool of 18 people was quickly reduced to 14 when initial cocaine amounts were 
detected. There were 4 patients that dropped out during treatment for unknown reasons, reducing 
the final sample size to 10 people. The authors of the study acknowledged these limitations and 
advocate for a larger trial to help strengthen the findings of future trials.4 
Terraneo et al 
 
 The Terraneo et al study3 was conducted in Italy by the Department of Outpatient 
Neuroscience at the University of Padua. It was a between subject, open label, RCT where 
eligible individuals were randomly assigned to a treatment group who received rTMS to the 
dorsal-lateral prefrontal cortex (DLPFC) or a control group who were administered an 
established protocol pharmacological treatment for CUD. Subjects were assessed for cocaine use 
during the study by urine analysis to quantify the outcome of the interventions. The study was 
divided into 3 stages: Stage 0 (recruitment), Stage 1 (29-day treatment), and Stage 2 (an 
additional 63-day follow-up). Secondary outcomes such as cocaine craving (see Figure 1) and 
depression were monitored during this study; however, because of the subjectivity of these 
outcomes and the Bollini et al study4 not measuring these outcomes, these results will not be 
discussed in depth.  
 Inclusion criteria for this study were patients between 18 and 70 years old, with a 
diagnosis of CUD, and actively seeking outpatient treatment for CUD. The study excluded 
subjects who were currently pregnant or had a diagnosis of major depressive disorder, bipolar 
disorder, schizophrenia, other psychotic disorders, or another substance use disorder. Medical 
exclusion criteria were subjects who had a history of epilepsy or seizures, or had electronic 
medical devices. Stage 0 yielded 32 qualifying participants who were randomized into standard 
(pharmacological) and experimental (rTMS) treatments.3 See Table 3. 
The pharmacologic intervention was established by the Department of Neuroscience at 
the University of Padua and consisted of pramipexole 0.35 mg TID, oxazepam 15 mg TID., 
bupropion 150 mg daily, triazolam 0.25 mg daily, and gamma hydroxybutyrate 1.75 g daily3. 
This combination of medications reduces cravings for substances as well as reducing anxiety, 
depression, and sleep symptoms that often accompany cocaine discontinuance. The experimental 
group received rTMS from a MagPro R30 stimulator device that was meticulously calibrated to 
target the subject’s left DLPFC. MRI was initially used to locate the desired point of stimulation, 
and the coordinates were marked on a cap with which the subject had been fitted. The cap was 
then used for the duration of treatment. The stimulation doses were delivered in 60 pulse trains at 
15 hz frequency. Forty simulation trains with 15 second rests were administered each session 
totaling 2400 total pulses per 13-minute treatment. Abstinence of alcohol use was a requirement 
for both groups and a daily dose of disulfiram, a medication which is an emetic if alcohol is 
ingested, was given to all participants to deter alcohol consumption.3  
The treatment period, Stage 1, was 29 days for both the experimental and the standard 
groups. The experimental group was given 1 rTMS treatment per day for the first 5 days, then 
once a week for the following 3 weeks, totaling 8 rTMS treatments. The standard group received 
pharmacologic treatment for the entire treatment stage.  
The follow-up period, Stage 2, lasted 63 days. During this time, the standard group was 
given the choice of continuing pharmacologic treatment or switching to rTMS treatment and 
tapering off the medication. Ten of the standard participants chose to switch to rTMS (n=10), 1 
discontinued the study, and 2 continued pharmacologic treatment. Both the standard and 
experimental group had one participant who discontinued treatment during the follow up period, 
resulting in a 6% loss of participants over the course of the trial.3 
The study reported a positive outcome if a subject did not test positive for cocaine on any 
of the urinalysis tests during the experimental phase and a negative outcome if there were any 
positive tests. The treatment group had 69% positive outcomes and the standard group had 19%, 
showing that there was a statistically significant positive outcome in the treatment group 
(p=0.035). The authors used a logistic regression model adjusted for age to determine whether 
the difference in ages of subjects in the standard and experimental group affected outcomes. 
There was still a statistically significant outcome when this was performed (p = 0.035) with an 
insignificant effect from age (p = 0.102). A Kaplan Meier curve was then conducted to confirm 
this finding (log rank p=0.0013).  
Stage 2 analysis showed that the standard group subjects that switched to rTMS in Stage 
2 had a significant reduction in negative outcomes compared to the standard group subjects who 
remained in pharmacologic treatment (McNemar Chi square, one tail, p=0.037). There was also 
no significant difference in positive outcomes between the treatment group in Stage 1 and the 
standard group subjects who switched to rTMS treatment in Stage 2 (p=0.64)3. This shows that 
the positive outcome in the treatment group in Stage 1 was not due to individual differences 
between the subjects in this group and the standard group.  
A secondary outcome of cocaine craving was logged during Stage 1, by patients rating a 
0-10 visual analog scale. Craving scores were lower in the treatment group than the standard 
group during Stage 1 (p=0.038). (See Figure 1.); however, there was no significant difference in 
craving scores between groups during Stage 2.3 
Another secondary outcome, depression, was measured to ensure that a difference in 
depression between the groups did not contribute to the primary outcome and to assess the 
effects of treatment on depression. Participants completed a SCL-90 depression subscale before 
treatment and during Stage 1 and Stage 2. Analysis showed no significant difference in 
depression between the 2 groups before treatment. In Stage 1, both groups showed an 
improvement in depression symptoms with no significant difference between groups.3  
The limitation of this study is most notably a small sample study size of 32 subjects. This 
sample size is larger than the Bolloni et al study,4 however, still a relatively small group. The 
authors recognized this limitation, as well as noting that the open label design had a potential for 
bias. There is a potential concern that the disulfiram administered to deter alcohol consumption 
may have also contributed to a decrease in cocaine use in both groups during treatment. This, 
however, does not decrease the significance of the difference in positive outcomes between the 
two groups since both groups received disulfiram in equal amounts.3  
DISCUSSION 
 Cocaine use disorder is a prevalent issue on both an international and national scale. One 
hundred and seventy thousand people were in rehabilitation treatment for CUD in North America 
in 2014.1 From 2000-2016, deaths from cocaine overdose increased every year and totaled 10619 
people, which does not include deaths from complications of chronic cocaine use.14 Most 
individuals with cocaine dependence are not able to recover without treatment. Even with 
treatment, 24% of patients relapse within one year.15 Cocaine’s ability to induce functional 
changes in the neuropathways of the prefrontal cortex that regulate impulsiveness and other 
executive functions10 make effective treatment particularly difficult. Due to the high mortality 
rate associated with cocaine use and no consistently proven effective treatments to date3, the need 
for new treatment approaches is imminent.  
rTMS is a noninvasive treatment that uses magnetic induction to create an intracranial 
electrical field significant enough to depolarize neurons, effectively stimulating them.3 In theory, 
stimulating the prefrontal cortex will ultimately reduce cocaine use behavior by “boosting” 
dopamine signaling in the brain.4 rTMS is an attractive treatment option due to its relatively short 
administration time, non-invasive nature, and mild adverse events.3,4 Since continued cocaine use 
holds such a high risk of mortality and social and economic dysfunction, the benefits of rTMS 
treatment far outweighs the adverse risks.  
Results of the 2 studies compiled in this analysis show a statistically significant reduction 
in cocaine use in the subjects who received rTMS treatment compared to other treatment in both 
short3 and long4 term time spans. The Terraneo et al study3 compares current pharmacological 
treatment of cocaine use disorder to rTMS treatment. The Terraneo et al study3 showed lower 
cocaine use in the group receiving rTMS during the treatment stage and through a 3 month 
follow up period after treatment. The Bolloni et al study4 showed a decrease in cocaine use in the 
group receiving rTMS during treatment and during a longer follow up period of 6 months. This 
study shows that rTMS treatment may require less than 2 treatments a year.  
The cost of treatment is a large barrier to CUD treatment since many individuals with 
CUD have lost their jobs and financial support. Most insurance companies cover rTMS for the 
treatment of depression since it is FDA approved for this condition, however, since the FDA has 
not approved rTMS for CUD, insurance coverage is variable for isolated CUD. More trials 
showing the effectiveness of rTMS treatment for CUD are required to gain FDA approval, and 
consequently insurance coverage. Many individuals with cocaine use disorder have co-morbid 
mental health disorders, including depression, which may indirectly allow them to have 
insurance coverage for rTMS. Without insurance, rTMS can range from $6 000 to $12 000. This 
may seem expensive until compared to the even greater cost of continued cocaine use and other 
current treatments for CUD. The out-of-pocket cost of inpatient CUD rehabilitation can be up to 
$100 000 making rTMS treatment a much cheaper alternative. 
Repetitive transcranial magnetic stimulation is generally well tolerated with mild adverse 
effects. The most common side effects are mild headache in half of patients and mild scalp pain 
or facial twitching in a third of patients. These effects do not cause most patients to stop 
treatment and usually resolve with progressive treatments. The most serious risk is rare instances 
of rTMS induced seizures, although precautions can be taken to minimize this. 12  
Psychotherapy is currently the most effective treatment for preventing relapse but there is 
a high rate of relapse if it is not augmented with another type of treatment. Studies on 
pharmacologic treatment for CUD show mixed results and high drop-out rates. The most 
common medications currently being used are methadone, dextroamphetamine, disulfram, and 
modanafil. These medications have adverse effects of their own13, making rTMS a good 
alternative.  
Small sample size is the most notable limitation of both studies reviewed here, which led 
to less precision in the outcomes. The combined sample size of the Bolloni et al4 and Terraneo et 
al3 studies was only 42 subjects. The high attrition rate of the Bolloni et al study4 is another 
notable limitation that decreased the precision of this study. The study originally recruited 18 
participants but lost 8 of them for various reasons before the data was analyzed, reducing the 
sample size by 44%. While the Terraneo et al study3 had a larger sample size and less attrition, 
the open-label study design increased the potential for biased outcomes. The Bollini et al4 study 
avoided selection bias by using a double-blind allocation sequence.  
While both studies3,4 have significant limitations, their results are promising and their 
designs can be used to inform future trials. Further trials would ideally start with larger sample 
sizes and use a double-blinded model. Although both trials showed the effectiveness of rTMS in 
reducing short term cocaine use in the short term, trials with follow up periods longer than 6 
months are needed to show whether rTMS has long-term effects on CUD.  
There was only one study9 currently in progress that was found on the subject of rTMS 
and CUD when a search of the National Institute of Health clinical trials website was performed. 
This trial is a double-blinded RCT that will compare rTMS treatment to a sham rTMS treatment 
for subjects with CUD. Cocaine use will be the primary outcome, with secondary outcomes of 
depression, anxiety, psychopathological symptoms, and changes in sleep quality. Outcomes will 
be gathered at baseline, immediately after rTMS treatment, and at 2 weeks, 3 months, 6 months, 
and 12 months post treatment.9 The study is still in the recruitment phase. The results of this 
study will provide more evidence as to whether or not rTMS should come to the forefront of 
clinical treatment of CUD. 
While both studies reviewed here have low to moderate levels of quality of evidence 
based on the GRADE criteria, the benefits of rTMS treatment seem to far outweigh the risk of 
adverse events of treatment and of continued cocaine use. Before a decision to receive rTMS 
treatment, patients should be informed of the limitations of research on rTMS and cocaine use 
and the adverse effects of rTMS, but also of the benefits of living a life free of cocaine use if 
rTMS treatment is successful. 
 
CONCLUSION 
While the studies assessing whether rTMS is effective for decreasing CUD use are few 
and have limitations, they show promising preliminary evidence to support rTMS as a treatment 
option. Larger studies with smaller attrition rates are required to prove the results found in the 
current studies. Head-to-head trials comparing other common treatments for CUD, such as 
different medication protocols, inpatient treatment, and psychotherapy, are required before the 
standard of care for individuals with CUD should include rTMS. It would also be beneficial to 
have studies done showing whether rTMS is effective as an adjunct therapy to current 
treatments. The study on this topic which is currently in process, with a larger sample size and 
double blinded RCT design, shows that there is continued interest in exploring this treatment. 
Before deciding on rTMS treatment, considerations such as insurance coverage and mild adverse 
effects must be reviewed with the individual. Due to the severe negative effects of cocaine use 
and the high risk of relapse with all current treatment options, rTMS should still be added to the 
list of options for treating CUD, especially for individuals who have failed other treatments.  
  
 
 
Table 1: Quality Assessment of Reviewed Articles 
Quality Assessment of Reviewed Articles 
Study Design 
Downgrade Criteria 
Upgrade 
Criteria 
Quality 
Limitations Indirectness Inconsistency Imprecision 
Publication 
bias 
Bolloni 
et al4 
RCT Not 
Serious 
Not Serious Not Serious Seriousa Unlikely None Moderate 
Terraneo 
et al5 
RCT Seriousb Not Serious Not Serious Seriousa Unlikely None Low 
a High attrition rate and/or small sample size 
b Open label study with no allocation concealment 
 
 
 
Table 2: Bolloni et al  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Demographic Characteristics at baseline (M+/- SD and ranges) 
  rTMS group (n=10) Control group (n=8) 
Gender (M/F) 9/1 7/1 
Age 33.9 +/- 6.5 (27-48) 
32.4 +/- 10.6 (23-
50) 
Education (years) 11 +/- 3.5 (8-13) 
11.75 +/- 2.31 (8-
13) 
Employed (yes/no) 7/3 4/4 
Duration of cocaine dependence 12.3 +/- 5.7 9.1 +/- 6.1 
Cocaine amount in hair (ng/mg) 11.31 8.77 
Table 3: Terraneo et al 
 
Participant Characteristics at Baseline 
  
rTMS group 
(n=16) 
Control group 
(n=16) 
Age 43.5 37.06 
Women 2 0 
Race: Caucasians (%) 100 100 
Age of first cocaine use 26.69 24.06 
Years of cocaine use 16.81 13 
Cocaine use during the last month (days per week) 4.81 4.31 
Cocaine use during the last month (grams per day) 1.81 1.75 
Tobacco: smokes (%) 62.5 56.25 
Last use:    
              Less than 24 h 37.50% 43.75% 
              Between 24 and 48 h 18.75% 25% 
              More than 48 h 43.75% 31.25% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Terraneo et al 
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